New drug cocktail aims to stop kidney rejection

NCT ID NCT03737136

Completed Disease control Sponsor: Shahid Beheshti University of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether adding the drug bortezomib to a standard treatment (rituximab, plasma exchange, and IVIG) helps control antibody-mediated rejection in kidney transplant patients. Twenty participants were enrolled, and researchers measured kidney function and rejection markers. The goal is to find better ways to keep transplanted kidneys working longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bortezomib (Velcade) added to rituximab, plasma exchange, and IVIG
What this could lead to: If adding bortezomib works better, it could improve kidney transplant survival and reduce rejection episodes.
What could go wrong: This is a very small, early study (20 people) with no phase designation. The results may not apply to all patients, and bortezomib can cause side effects like nerve damage and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection chronic transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBODY MEDIATED REJECTION

Contacts and locations

Locations

SBMU

Tehran, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.